Filtered By:
Specialty: Drugs & Pharmacology
Condition: Heart Failure

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 434 results found since Jan 2013.

The Impact of Heart Failure and Left Ventricular Dysfunction in Predicting Stroke, Thromboembolism, and Mortality in Atrial Fibrillation Patients: A Systematic Review.
Abstract PURPOSE: Atrial fibrillation (AF) is commonly associated with structural heart disease. Although heart failure (HF) has been proposed as a risk factor for stroke, the coexistence of the 2 diseases increases disproportionally the risk of thromboembolic events. Our objective was to conduct a systematic review to assess the effect of HF on the end points of stroke, systemic embolism (SE), or mortality in patients with AF. METHODS: A literature search was performed to identify studies that examined stroke/ SE in relation to AF and HF. Overall, 405 articles satisfied the preinclusion criteria. FINDIN...
Source: Clinical Therapeutics - August 18, 2014 Category: Drugs & Pharmacology Authors: Agarwal M, Apostolakis S, Lane DA, Lip GY Tags: Clin Ther Source Type: research

Atrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation.
Abstract Atrial fibrillation (AF) is a common arrhythmia increasing the risk of morbidity and adverse outcomes (stroke, heart failure, death). AF is found in 1-2% of the general population, with increasing prevalence with aging. Its exact epidemiological profile is incomplete and underestimated, because 10-40% of AF patients (particularly the elderly) can be asymptomatic ("clinically silent or subclinical AF"), with occasional electrocardiographic diagnosis. The research interest on silent AF has increased by the evidence that its outcome is no less severe, in terms of risks of stroke and death, than that for symp...
Source: Vascular Pharmacology - May 15, 2016 Category: Drugs & Pharmacology Authors: Boriani G, Pettorelli D Tags: Vascul Pharmacol Source Type: research

Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke.
CONCLUSIONS: It is unlikely that SGLT inhibitors have a positive or negative effect on stroke risk, but the question that remains unanswered is whether SGLT inhibitors can yield a protective effect after acute ischemic stroke. Future observational studies and registries may be the first step to help answer this question. (Clin Ther. 2020; XX:XXX-XXX) © 2020 Elsevier HS Journals, Inc. PMID: 33008610 [PubMed - as supplied by publisher]
Source: Clinical Therapeutics - September 28, 2020 Category: Drugs & Pharmacology Authors: Al Hamed FA, Elewa H Tags: Clin Ther Source Type: research

Efficacy of Calcium Channel Blockers Versus Other Classes of Antihypertensive Medication in the Treatment of Hypertensive Patients With Previous Stroke and/or Coronary Artery Disease: A Systematic Review and Meta-Analysis
Hypertensive patients, such as those with established coronary artery disease (CAD) or those who have suffered a stroke, are at increased risk of morbidity and mortality. This systematic literature review and meta-analysis assesses the long-term effects of calcium channel blockers (CCBs) compared with other classes of antihypertensive medications on major cardiovascular (CV) outcomes in these high-risk subgroups of hypertensive patients. Randomized, active controlled parallel group trials were included if they compared CCBs with α-blockers, β-blockers, angiotensin II receptor blockers, angiotensin-converting enzyme inhib...
Source: American Journal of Therapeutics - January 1, 2017 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research

Stroke Risk Scores as Predictors of Severe Outcomes in Atrial Fibrillation: A Comprehensive Review
Background: Atrial fibrillation (AF) is the most frequent sustained arrhythmia. It increases the risk of stroke, heart failure, death, hospitalizations, and costs. Area of uncertainty: Several scores were introduced to stratify the stroke risk and need for anticoagulation in patients (pts) with AF . CHA2DS2-VASc, the most frequently used score, as well as other stroke risk scores have been additionally applied to estimate outcomes for different other conditions, with inhomogeneous results. To date, there has been no consensus regarding the usefulness of these scores to estimate outcomes outside of thromboembolic...
Source: American Journal of Therapeutics - May 1, 2021 Category: Drugs & Pharmacology Tags: Systematic Review and Clinical Guidelines Source Type: research

Cost‐Effectiveness of High‐Dose Edoxaban Compared with Adjusted‐Dose Warfarin for Stroke Prevention in Non–Valvular Atrial Fibrillation Patients
ConclusionsHigh‐dose edoxaban appears to be an economically dominant strategy when compared with adjusted‐dose warfarin for the prevention of stroke in NVAF patients with a Clcr of 15–95 ml/minute and an appreciable risk of stroke.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 26, 2016 Category: Drugs & Pharmacology Authors: Elaine Nguyen, Florence Egri, Elizabeth S. Mearns, Charles M. White, Craig I. Coleman Tags: Original Research Article Source Type: research

Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation
ConclusionsThe uptake of DOACs was rapid and spurred an increase in new users of oral anticoagulants for atrial fibrillation from 2010 to 2015 in Norway. The mean CHA2DS2-VASc score did not change substantially during this period. Vascular disease, heart failure, and diabetes were associated with initiation of warfarin, and previous stroke, age 65 –74 and female sex with initiation of DOACs.
Source: European Journal of Clinical Pharmacology - August 16, 2018 Category: Drugs & Pharmacology Source Type: research

Oral levosimendan increases cerebral blood flow velocities in patients with a history of stroke or TIA – a pilot safety study
Conclusions Oral levosimendan increases cerebral blood flow velocities and diminishes NT-pro-BNP levels in patients with earlier ischaemic cerebrovascular event. Daily doses up to 1.0 mg were well-tolerated, whereas 2.0 mg dose level induced an increase in ventricular extrasystoles. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00698763
Source: Current Therapeutic Research - January 29, 2015 Category: Drugs & Pharmacology Source Type: research

INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation
Conclusion The intensity of anticoagulation therapy for Korean patients with NVAF is optimal when INR is between 1.7 and 2.2.
Source: International Journal of Clinical Pharmacy - June 12, 2015 Category: Drugs & Pharmacology Source Type: research

Beta-blockers are associated with decreased in-hospital mortality and stroke in acute decompensated heart failure: Findings from a retrospective analysis of a 22-year registry in the Middle East (1991-2013).
CONCLUSIONS: Previous beta-blockade therapy in patients presenting with ADHF decreases intra-hospital mortality and the incidence of CV events and transient ischemic attacks. Moreover, non-withdrawal of beta-blockers during hospitalization has a favorable outcome. PMID: 27550053 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - August 21, 2016 Category: Drugs & Pharmacology Authors: Khalil CA, Al Suwaidi J, Singh R, Asaad N, Abushahba G, Kunju U, Al-Qahtani A, AlBinali HA Tags: Curr Vasc Pharmacol Source Type: research

Long-Term Use of Statins Lowering the Risk of Rehospitalization Caused by Ischemic Stroke Among Middle-Aged Hyperlipidemic Patients: A Population-Based Study
Conclusion: Statins were associated with long-term secondary prevention of reHospIS for hyperlipidemic patients. Rosuvastatin seemed to have the best protective effects. On the other hand, Bezafibrate appears to be beneficial for hyperlipidemic patients developing diabetes. Further research into the combination treatment of statin and nonstatin lipid-lowering medicines in hyperlipidemic patients developing diabetes is warranted.
Source: Frontiers in Pharmacology - October 18, 2021 Category: Drugs & Pharmacology Source Type: research

Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation
Expert Opin Investig Drugs. 2021 Mar 8. doi: 10.1080/13543784.2021.1897786. Online ahead of print.ABSTRACTINTRODUCTION: Atrial fibrillation is the most frequently diagnosed cardiac arrhythmia globally and is associated with ischemic stroke and heart failure. Patients with atrial fibrillation are typically prescribed long term anticoagulants in the form of either vitamin K antagonists or non-vitamin K antagonist oral anticoagulants; however, both carry a potential risk of adverse bleeding.AREAS COVERED: This paper sheds light on emerging anticoagulant agents which target clotting factors XI and XII, or their activated forms...
Source: Expert Opinion on Investigational Drugs - March 8, 2021 Category: Drugs & Pharmacology Authors: Robert Bentley Lewis J Hardy Laura J Scott Parveen Sharma Helen Philippou Gregory Y H Lip Source Type: research